J Rheum Dis.  2020 Jul;27(3):182-202. 10.4078/jrd.2020.27.3.182.

The Practice Guideline for Vaccinating Korean Patients With Autoimmune Inflammatory Rheumatic Disease

• Seo YB
• Moon SJ
• Jeon CH
• Song JY
• Sung YK
• Jeong SJ
• Kwon KT
• Kim ES
• Kim JH
• Kim HA
• Park DJ
• Park SH
• Park JK
• Ahn JK
• Oh JS
• Yun JW
• Lee JH
• Lee HY
• Choi MJ
• Choi WS
• Choi YH
• Choi JH
• Heo JY
• Cheong HJ
• Lee SS

• KMID: 2504034
• DOI: http://doi.org/10.4078/jrd.2020.27.3.182

Abstract

To develop a clinical practice guideline for vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), the Korean College of Rheumatology and the Korean Society of Infectious Diseases developed a clinical practice guideline according to the clinical practice guideline development manual. Since vaccination is unlikely to cause AIIRD or worsen disease activities, required vaccinations are recommended. Once patients are diagnosed with AIIRD, treatment strategies should be established and, at the same time, monitor their vaccination history. It is recommended to administer vaccines when the disease enters the stabilized stage. Administering live attenuated vaccines in patients with AIIRD who are taking immunosuppressants should be avoided. Vaccination should be considered in patients with AIIRD, prior to initiating immunosuppressants. It is recommended to administer influenza, Streptococcus pneumoniae, hepatitis A, hepatitis B, herpes zoster, measles-mumps-rubella virus, human papillomavirus, and tetanus-diphtheria-pertussis vaccines in patients with AIIRD; such patients who planned to travel are generally recommended to be vaccinated at the recommended vaccine level of healthy adults. Those who live in a household with patients with AIIRD and their caregivers should also be vaccinated at levels that are generally recommended for healthy adults.

Keyword

Autoimmune inflammatory rheumatic disease; Vaccine; Immunization; Guideline

Figure

• 

  Figure 1 Procedure for searching and screening literature for adapting a practice guideline. AGREE: Appraisal of Guidelines Research and Evaluation.

Reference

1. Falagas ME, Voidonikola PT, Angelousi AG. 2007; Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents. 30:477–86. DOI: 10.1016/j.ijantimicag.2007.07.010. PMID: 17913470.

2. Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. 2010; Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 49:1815–27. DOI: 10.1093/rheumatology/keq183. PMID: 20591834. PMCID: PMC2936949.

3. Bosch X, Guilabert A, Pallarés L, Cerveral R, Ramos-Casals M, Bové A, et al. 2006; Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 15:584–9. DOI: 10.1177/0961203306071919. PMID: 17080913.

4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. 2002; Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 46:2294–300. DOI: 10.1002/art.10529. PMID: 12355476.

5. Martin-Mola E, Balsa A. 2009; Infectious complications of biologic agents. Rheum Dis Clin North Am. 35:183–99. DOI: 10.1016/j.rdc.2009.03.009. PMID: 19481004.

6. Furst DE. 2010; The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 39:327–46. DOI: 10.1016/j.semarthrit.2008.10.002. PMID: 19117595.

7. Glück T, Müller-Ladner U. 2008; Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis. 46:1459–65. DOI: 10.1086/587063. PMID: 18419456.

8. Hmamouchi I, Winthrop K, Launay O, Dougados M. 2015; Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine. 33:1446–52. DOI: 10.1016/j.vaccine.2015.01.065. PMID: 25659279.

9. Kim SY, Choi MY, Shin SS, Ji SM, Park JJ, Yoo JH, et al. 2015. Handbook for clinical practice guideline developer version 1.0. National Entertainment Collectibles Association;Seoul: p. 1–428.

10. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. 2012; AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 7:e33536. DOI: 10.1371/journal.pone.0033536. PMID: 22470453. PMCID: PMC3314666.

11. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. 2014; Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 13:600–13. DOI: 10.1016/S1474-4422(14)70075-4.

12. Mantadakis E, Farmaki E, Buchanan GR. 2010; Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 156:623–8. DOI: 10.1016/j.jpeds.2009.10.015. PMID: 20097358.

13. Andrews N, Stowe J, Miller E, Svanström H, Johansen K, Bonhoeffer J, et al. VAESCO consortium. 2012; A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. Vaccine. 30:3042–6. DOI: 10.1016/j.vaccine.2011.06.009. PMID: 21699947.

14. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. 2001; Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 84:227–9. DOI: 10.1136/adc.84.3.227. PMID: 11207170. PMCID: PMC1718684.

15. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. 2009; Adjuvants and autoimmunity. Lupus. 18:1217–25. DOI: 10.1177/0961203309345724. PMID: 19880572.

16. Wraith DC, Goldman M, Lambert PH. 2003; Vaccination and autoimmune disease: what is the evidence? Lancet. 362:1659–66. DOI: 10.1016/S0140-6736(03)14802-7.

17. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. 2013; Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun. 47:1–16. DOI: 10.1016/j.jaut.2013.10.004. PMID: 24238833.

18. Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al. 1978; Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med. 88:790–2. DOI: 10.7326/0003-4819-88-6-790. PMID: 307356.

19. Zycinska K, Romanowska M, Nowak I, Rybicka K, Wardyn KA, Brydak LB. 2007; Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J Physiol Pharmacol. 58 Suppl 5(Pt 2):819–28.

20. Ristow SC, Douglas RG Jr, Condemi JJ. 1978; Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med. 88:786–9. DOI: 10.7326/0003-4819-88-6-786. PMID: 666135.

21. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. Infectious Diseases Society of America. 2014; 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 58:309–18. DOI: 10.1093/cid/cit816. PMID: 24421306.

22. Cordeiro I, Duarte AC, Ferreira JF, Gonçalves MJ, Meirinhos T, Rocha TM, et al. 2016; Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the Portuguese Society of Rheumatology. Acta Reumatol Port. 41:112–30.

23. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. 2011; EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 70:414–22. DOI: 10.1136/ard.2010.137216. PMID: 21131643.

24. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68:1–26. DOI: 10.1002/art.39480. PMID: 26545940.

25. Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, et al. 2015; Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 145:w14159. DOI: 10.4414/smw.2015.14159. PMID: 26218860.

26. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association. 2012; recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol. 39:1583–602. DOI: 10.3899/jrheum.120165. PMID: 22707613.

27. Ledingham J, Deighton C. British Society for Rheumatology Standards, Guidelines and Audit Working Group. 2005; Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 44:157–63. DOI: 10.1093/rheumatology/keh464. PMID: 15637039.

28. Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, et al. Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). 2008; Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine. 75(Suppl 1):S1–99. DOI: 10.1016/S1297-319X(08)73620-0. PMID: 18708020.

29. Pham T, Claudepierre P, Constantin A, de Bandt M, Fautrel B, Gossec L, et al. Club Rhumatismes et Inflammation (CRI). 2010; Tocilizumab: therapy and safety management. Joint Bone Spine. 77(Suppl 1):S3–100. DOI: 10.1016/S1297-319X(10)70001-4. PMID: 20610315.

30. Pham T, Claudepierre P, Constantin A, Fautrel B, Gossec L, Gottenberg JE, et al. 2009; Abatacept therapy and safety management. Joint Bone Spine. 76(Suppl 1):S3–55. DOI: 10.1016/S1297-319X(09)74520-8. PMID: 19560051.

31. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P, et al. Club Rhumatismes et Inflammation, French Society of Rheumatology. 2005; Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine. 72(Suppl 1):S1–58.

32. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. 2006; Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 45:106–11. DOI: 10.1093/rheumatology/kei193. PMID: 16287919.

33. Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, et al. 2008; Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine. 26:3528–33. DOI: 10.1016/j.vaccine.2008.04.028. PMID: 18502006.

34. Kaine JL, Kivitz AJ, Birbara C, Luo AY. 2007; Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 34:272–9. PMID: 17304653.

35. Ribeiro AC, Laurindo IM, Guedes LK, Saad CG, Moraes JC, Silva CA, et al. 2013; Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 65:476–80. DOI: 10.1002/acr.21838. PMID: 22949223.

36. Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. 2015; Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 74:818–22. DOI: 10.1136/annrheumdis-2013-204427. PMID: 24448345. PMCID: PMC4392200.

37. Hua C, Barnetche T, Combe B, Morel J. 2014; Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 66:1016–26. DOI: 10.1002/acr.22246. PMID: 24339395.

38. Morel J, Czitrom SG, Mallick A, Sellam J, Sibilia J. 2016; Vaccinations in adults with chronic inflammatory joint disease: immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. Joint Bone Spine. 83:135–41. DOI: 10.1016/j.jbspin.2015.08.008. PMID: 26453106.

39. Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, et al. 2018; Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol. 24:138–47. DOI: 10.1097/RHU.0000000000000624. PMID: 29232324.

40. Tanrıöver MD, Akar S, Türkçapar N, Karadağ Ö, Ertenli İ, Kiraz S. 2016; Vaccination recommendations for adult patients with rheumatic diseases. Eur J Rheumatol. 3:29–35. DOI: 10.5152/eurjrheum.2016.16100. PMID: 27708966. PMCID: PMC5042271.

41. Staples JE, Gershman M, Fischer M. Centers for Disease Control and Prevention (CDC). 2010; Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 59:1–27.

42. Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, et al. 1997; Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 175:1–6. DOI: 10.1093/infdis/175.1.1. PMID: 8985189. PMCID: PMC7109672.

43. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. 2000; Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet. 355:93–7. DOI: 10.1016/S0140-6736(99)05190-9. PMID: 10675165.

44. Babcock HM, Gemeinhart N, Jones M, Dunagan WC, Woeltje KF. 2010; Mandatory influenza vaccination of health care workers: translating policy to practice. Clin Infect Dis. 50:459–64. DOI: 10.1086/650752. PMID: 20064039.

45. Pearson ML, Bridges CB, Harper SA. Healthcare Infection Control Practices Advisory Committee (HICPAC). Advisory Committee on Immunization Practices (ACIP). 2006; Influenza vaccination of health-care personnel: recommendations of the and the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 55:1–16. DOI: 10.1037/e506932006-001.

46. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). 2007; Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 56:1–40.

47. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al. 2000; The postmarketing safety profile of varicella vaccine. Vaccine. 19:916–23. DOI: 10.1016/S0264-410X(00)00297-8.

48. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. 2006; Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr. 148:842–4. DOI: 10.1016/j.jpeds.2006.01.038. PMID: 16769402.

49. Nichol KL, Wuorenma J, von Sternberg T. 1998; Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 158:1769–76. DOI: 10.1001/archinte.158.16.1769. PMID: 9738606.

50. Blumentals WA, Arreglado A, Napalkov P, Toovey S. 2012; Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 13:158. DOI: 10.1186/1471-2474-13-158. PMID: 22925480. PMCID: PMC3495205.

51. Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, et al. 1994; Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 21:1203–6. PMID: 7966058.

52. Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. 2006; Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 24:3217–23. DOI: 10.1016/j.vaccine.2006.01.028. PMID: 16466833.

53. Denman EJ, Denman AM, Greenwood BM, Gall D, Heath RB. 1970; Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis. 29:220–31. DOI: 10.1136/ard.29.3.220. PMID: 4194200. PMCID: PMC1031255.

54. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. 2010; The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 39:442–7. DOI: 10.1016/j.semarthrit.2008.12.002. PMID: 19246078.

55. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. 2006; Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 65:191–4. DOI: 10.1136/ard.2005.036434. PMID: 16014674. PMCID: PMC1798034.

56. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. 2008; The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 67:713–6. DOI: 10.1136/ard.2007.077552. PMID: 17965123.

57. Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al. 1979; Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 242:53–6. DOI: 10.1001/jama.1979.03300010037025. PMID: 312949.

58. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. 2007; Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 17:531–3. DOI: 10.3109/s10165-007-0632-5. PMID: 18084712.

59. Nii T, Kubota T, Nanki T, Komano Y, Harigai M, Kohsaka H, et al. 2009; Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod Rheumatol. 19:216–8. DOI: 10.3109/s10165-008-0135-z. PMID: 19015815.

60. Turner-Stokes L, Cambridge G, Corcoran T, Oxford JS, Snaith ML. 1988; In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis. 47:532–5. DOI: 10.1136/ard.47.7.532. PMID: 3261154. PMCID: PMC1003565.

61. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. 2010; Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 62:75–81. DOI: 10.1002/art.25033. PMID: 20039396.

62. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. 1978; Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med. 88:729–34. DOI: 10.7326/0003-4819-88-6-729. PMID: 352210.

63. Holvast B, Huckriede A, Kallenberg CG, Bijl M. 2007; Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun Rev. 6:300–5. DOI: 10.1016/j.autrev.2006.09.012. PMID: 17412302.

64. Mercado U, Acosta H, Avendaño L. 2004; Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin. 56:16–20. DOI: 10.7326/0003-4819-88-6-786. PMID: 15144037.

65. Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalińska-Sadowska H, Brydak LB, Olesińska M, et al. 2010; Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol. 29:605–13. DOI: 10.1007/s10067-010-1373-y. PMID: 20140692.

66. Caza T, Oaks Z, Perl A. 2014; Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol. 33:330–63. DOI: 10.3109/08830185.2013.863305. PMID: 24471448.

67. Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. 2012; Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology (Oxford). 51:1061–9. DOI: 10.1093/rheumatology/ker427. PMID: 22298793.

68. Brodman R, Gilfillan R, Glass D, Schur PH. 1978; Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med. 88:735–40. DOI: 10.7326/0003-4819-88-6-735. PMID: 307353.

69. Pons VG, Reinertsen JL, Steinberg AD, Dolin R. 1979; Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol. 4:15–23. DOI: 10.1002/jmv.1890040103. PMID: 231095.

70. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. 2009; Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 60:2438–47. DOI: 10.1002/art.24679. PMID: 19644961.

71. Setti M, Fenoglio D, Ansaldi F, Filaci G, Bacilieri S, Sticchi L, et al. 2009; Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine. 27:3367–72. DOI: 10.1016/j.vaccine.2009.01.078. PMID: 19200840.

72. Holvast A, Stegeman CA, Benne CA, Huckriede A, Wilschut JC, Palache AM, et al. 2009; Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis. 68:873–8. DOI: 10.1136/ard.2008.092924. PMID: 18625625.

73. Pasoto SG, Ribeiro AC, Viana VS, Leon EP, Bueno C, Neto ML, et al. 2013; Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome. Vaccine. 31:1793–8. DOI: 10.1016/j.vaccine.2013.01.057. PMID: 23395584.

74. Kobashigawa T, Nakajima A, Taniguchi A, Inoue E, Tanaka E, Momohara S, et al. 2013; Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol. 42:445–50. DOI: 10.3109/03009742.2013.788733. PMID: 23724971.

75. Stojanovich L. 2006; Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol. 13:373–5. DOI: 10.1080/17402520600800820. PMID: 17162380. PMCID: PMC2270765.

76. Torres A, Peetermans WE, Viegi G, Blasi F. 2013; Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 68:1057–65. DOI: 10.1136/thoraxjnl-2013-204282. PMID: 24130229. PMCID: PMC3812874.

77. Rákóczi É, Szekanecz Z. 2017; Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 3:e000484. DOI: 10.1136/rmdopen-2017-000484. PMID: 28955497. PMCID: PMC5604716.

78. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. 2002; Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis. 34:147–53. DOI: 10.1086/338043. PMID: 11740700.

79. Karsh J, Pavlidis N, Schiffman G, Moutsopoulos HM. 1980; Immunization of patients with Sjögren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum. 23:1294–8. DOI: 10.1002/art.1780231111. PMID: 7004446.

80. Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC. 2018; Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. Rheumatology (Oxford). 57:625–30. DOI: 10.1093/rheumatology/kex471. PMID: 29325173.

81. Nived P, Saxne T, Geborek P, Mandl T, Skattum L, Kapetanovic MC. 2018; Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment. BMC Rheumatol. 2:12. DOI: 10.1186/s41927-018-0019-6. PMID: 30886963. PMCID: PMC6390610.

82. Grabar S, Groh M, Bahuaud M, Le Guern V, Costedoat-Chalumeau N, Mathian A, et al. 2017; Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study. Vaccine. 35:4877–85. DOI: 10.1016/j.vaccine.2017.07.094. PMID: 28784280.

83. Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, et al. 2017; Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 35:3639–46. DOI: 10.1016/j.vaccine.2017.05.044. PMID: 28552512.

84. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. 1998; Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 41:1828–34. DOI: 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T. PMID: 9778224.

85. Izumi Y, Akazawa M, Akeda Y, Tohma S, Hirano F, Ideguchi H, et al. 2017; The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther. 19:15. DOI: 10.1186/s13075-016-1207-7. PMID: 28122642. PMCID: PMC5264490.

86. Watad A, Quaresma M, Brown S, Cohen Tervaert JW, Rodríguez-Pint I, Cervera R, et al. 2017; Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome)-an update. Lupus. 26:675–81. DOI: 10.1177/0961203316686406. PMID: 28059022.

87. Hügle T, Bircher A, Walker UA. 2012; Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet's disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology (Oxford). 51:761–2. DOI: 10.1093/rheumatology/ker388. PMID: 22157598.

88. Felicetti P, Trotta F, Bonetto C, Santuccio C, Brauchli Pernus Y, Burgner D, et al. 2016; Spontaneous reports of vasculitis as an adverse event following immunization: a descriptive analysis across three international databases. Vaccine. 34:6634–40. DOI: 10.1016/j.vaccine.2015.09.027. PMID: 26392009.

89. Choi MJ, Kang SO, Oh JJ, Park SB, Kim MJ, Cheong HJ. 2018; Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Hum Vaccin Immunother. 14:1914–22. DOI: 10.1080/21645515.2018.1456602. PMID: 29953307. PMCID: PMC6149703.

90. Russell FM, Carapetis JR, Balloch A, Licciardi PV, Jenney AW, Tikoduadua L, et al. 2010; Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial. Vaccine. 28:3341–9. DOI: 10.1016/j.vaccine.2010.02.087. PMID: 20206670. PMCID: PMC2854305.

91. Tanaka E, Urata Y. 2012; Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatol Res. 42:333–9. DOI: 10.1111/j.1872-034X.2011.00937.x. PMID: 22150950.

92. Oshima Y, Tsukamoto H, Tojo A. 2013; Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol. 23:694–704. DOI: 10.3109/s10165-012-0709-7. PMID: 22802011.

93. Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H. 2014; Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 33:577–86. DOI: 10.1007/s10067-013-2450-9. PMID: 24343455. PMCID: PMC3962582.

94. Chen MH, Chen MH, Liu CY, Tsai CY, Huang DF, Lin HY, et al. 2017; Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 215:566–73. DOI: 10.1093/infdis/jiw606. PMID: 28011918.

95. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2016; 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 68:1–25. DOI: 10.1002/acr.22783. PMID: 26545825.

96. The Korean Society of Infectious Diseases. 2012. Vaccination for adult. 2nd ed. MIP;Seoul:

97. Intongkam S, Samakarnthai P, Pakchotanon R, Narongroeknawin P, Assavatanabodee P, Chaiamnuay S. 2019; Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. J Clin Rheumatol. 25:329–34. DOI: 10.1097/RHU.0000000000000877. PMID: 31764493.

98. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. 2011; Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 70:1719–25. DOI: 10.1136/ard.2010.148783. PMID: 21719446.

99. Wang Q, Klenerman P, Semmo N. 2017; Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2:123–34. DOI: 10.1016/S2468-1253(16)30076-0. PMID: 28403982.

100. Elkayam O, Yaron M, Caspi D. 2002; Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 61:623–5. DOI: 10.1136/ard.61.7.623. PMID: 12079904. PMCID: PMC1754139.

101. Kim KA, Lee A, Ki M, Jeong SH. 2017; Nationwide seropositivity of hepatitis A in Republic of Korea from 2005 to 2014, before and after the outbreak peak in 2009. PLoS One. 12:e0170432. DOI: 10.1371/journal.pone.0170432. PMID: 28099530. PMCID: PMC5242508.

102. Askling HH, Rombo L, van Vollenhoven R, Hallén I, Thörner Å, Nordin M, et al. 2014; Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 12:134–42. DOI: 10.1016/j.tmaid.2014.01.005. PMID: 24529746.

103. Lee YH, Choe JY, Park SH, Park YW, Lee SS, Kang YM, et al. 2010; Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci. 25:1431–7. DOI: 10.3346/jkms.2010.25.10.1431. PMID: 20890422. PMCID: PMC2946651.

104. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. 2004; Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 50:3619–25. DOI: 10.1002/art.20616. PMID: 15529372.

105. Tam LS, Chan PK, Ho SC, Yu MM, Yim SF, Cheung TH, et al. 2010; Natural history of cervical papilloma virus infection in systemic lupus erythematosus-a prospective cohort study. J Rheumatol. 37:330–40. DOI: 10.3899/jrheum.090644. PMID: 20032093.

106. Anderson EJ. 2008; Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis. 8:642–9. DOI: 10.1016/S1473-3099(08)70231-7. PMID: 18922486.

107. Mok CC, Ho LY, Fong LS, To CH. 2013; Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 72:659–64. DOI: 10.1136/annrheumdis-2012-201393. PMID: 22589375.

108. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. 2009; Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 302:750–7. DOI: 10.1001/jama.2009.1201. PMID: 19690307.

109. Nies K, Boyer R, Stevens R, Louie J. 1980; Anti-tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. Arthritis Rheum. 23:1343–50. DOI: 10.1002/art.1780231203. PMID: 7006611.

110. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. 2010; Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 62:64–74. DOI: 10.1002/art.25034. PMID: 20039397.

111. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. 2007; Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther. 9:R38. DOI: 10.1186/ar2174. PMID: 17425783. PMCID: PMC1906816.

112. Abe T, Homma M. 1971; Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses. Acta Rheumatol Scand. 17:35–46. DOI: 10.3109/rhe1.1971.17.issue-1-4.06. PMID: 5546993.

113. Devey ME, Bleasdale K, Isenberg DA. 1987; Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 68:562–9. PMID: 3652524. PMCID: PMC1542762.

114. Kashef S, Ghazizadeh F, Derakhshan A, Farjadian S, Alyasin S. 2008; Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol. 5:181–4. DOI: IJIv5i3A7. PMID: 18791286.

115. Westra J, Rondaan C, van Assen S, Bijl M. 2015; Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 11:135–45. DOI: 10.1038/nrrheum.2014.206. PMID: 25486980.

116. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al. 2011; The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 13:R174. DOI: 10.1186/ar3497. PMID: 22024532. PMCID: PMC3308109.

117. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. 2012; Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 308:43–9. DOI: 10.1001/jama.2012.7304. PMID: 22760290. PMCID: PMC3683869.

118. Yun H, Xie F, Baddley JW, Winthrop K, Saag KG, Curtis JR. 2017; Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 44:1083–7. DOI: 10.3899/jrheum.160685. PMID: 28298565. PMCID: PMC5724562.

119. Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, et al. 2013; Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 40:1875–80. DOI: 10.3899/jrheum.130170. PMID: 24037550. PMCID: PMC3867792.

120. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. 2018; Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 67:103–8. DOI: 10.15585/mmwr.mm6703a5. PMID: 29370152. PMCID: PMC5812314.

121. Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et al. 2014; Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 133:961–6. DOI: 10.1016/j.jaci.2013.11.043. PMID: 24582311. PMCID: PMC4009347.

122. Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. 2013; Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 309:2449–56. DOI: 10.1001/jama.2013.6768. PMID: 23780457.

123. Borte S, Liebert UG, Borte M, Sack U. 2009; Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 48:144–8. DOI: 10.1093/rheumatology/ken436. PMID: 19074187.

124. Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. 2017; Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation-a systematic review of randomized trials, observational studies and case reports. Vaccine. 35:1216–26. DOI: 10.1016/j.vaccine.2017.01.048. PMID: 28162821.